Found 1,117 articles
Incyte (Nasdaq:INCY) today reports 2022 first quarter financial results, and provides a status update on the Company’s clinical development portfolio.
Several biopharma companies are closing out the month of April with expansions to facilities, including a $3 billion investment to develop next-generation life science ecosystems.
MorphoSys AG will publish its results for the first quarter 2022 on May 4, 2022 at 10:00 pm CEST.
Today, Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies.
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
I-Mab announced financial results for the 12 months ended December 31, 2021, and provided key business updates.
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and full year 2021.
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
MorphoSys U.S. Inc. announced that the National Comprehensive Cancer Network Clinical Practice Guidelines ) in Oncology for B-cell Lymphomas have been updated, and the designation for Monjuvi in combination with lenalidomide is now a Preferred Regimen for second-line therapy in patients with Diffuse Large B-cell Lymphoma who are not candidates for transplant.
The drop in value has prompted MorphoSys to make drastic changes, such as discontinuing its U.S. operations and abandoning several pipeline projects.
MorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021
MorphoSys AG announces that it will account for a non-cash impairment charge on goodwill in the amount of approximately € 231 million.
MorphoSys AG ; will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm CET.
The clinical trial, called SKYLINE, is starting without results from other key ongoing studies on the drug.
Xencor, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a review of recent business and clinical highlights.
Muscle Wasting Disorders Market: Cancer disease indication segment is anticipated to constitute a major share of the market in the near future
Muscle wasting is also known as muscle atrophy, which causes weakening of muscle tissue. Muscle atrophy causes a substantial decrease in muscle strength and ability of muscle movement.
LinKinVax, a clinical-stage biotechnology company is announcing completion of a €4.350 million seed capital funding round.
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
Incyte reports 2021 fourth quarter financial results, provides 2022 financial guidance and a status update on the Company’s clinical development portfolio.
Oncoinvent AS announces that Adrian Senderowicz was elected as a Non-executive Director today at the Company's Extraordinary General Meeting.
Alligator Bioscience Alligator Bioscience, announces the appointment of Sumeet Ambarkhane, MD, as its Chief Medical Officer.
1/28/2022Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
I-Mab announced the signing of a partnership agreement with the Hangzhou Qiantang New Area in China to manufacture its innovative drugs locally and accelerate its transition to commercialization.